Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954636 | 0.93 | NR3C2 (0.39) | TGFBR1NR3C2LRRK2PLATPDE10A | |
| SCHEMBL19954631 | 0.89 | TGFBR1 (0.43) | TGFBR1NR3C2LRRK2PDE10A | |
| SCHEMBL15069885 | 0.87 | MAPK13 (0.40) | LRRK2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL19954641 | 0.85 | NR3C1 (0.35) | TGFBR1NR3C2L3MBTL1 | |
| SCHEMBL19954623 | 0.85 | CYP1A2 (0.32) | TGFBR1LRRK2 | |
| SCHEMBL19954603 | 0.82 | TRPV4 (0.43) | TGFBR1NR3C2LMNAGAATRPV4 | |
| SCHEMBL25745871 | 0.81 | MAPK13 (0.47) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL24815018 | 0.79 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL21780763 | 0.79 | GAA (0.40) | TGFBR1NR3C2LRRK2PDE10AKDM4E | |
| SCHEMBL24815019 | 0.77 | NTRK1 (0.37) | TGFBR1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032256-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-02-04 | — | — | US | disclosed |
| US-10807988-B2 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | Grünenthal GmbH (DE) | 2020-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032256-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | TGFBR1 4618/4885NR3C2 12/4885LRRK2 3854/4885 |
| US-10807988-B2 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | OPRK1, OPRD1, OPRL1 | TGFBR1 4618/4885NR3C2 12/4885LRRK2 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.